Unlock instant, AI-driven research and patent intelligence for your innovation.

Aplidine for multiple myeloma treatment

a technology of multiple myeloma and aplidine, which is applied in the field of aplidine and analogues in the treatment of cancer, can solve the problems of renal failure, too many antibodies of one type, and many organ dysfunctions, and achieves potent in vitro activity, confirmed selectivity, and lack of severe myelosuppression.

Active Publication Date: 2007-06-28
PHARMA MAR U +1
View PDF20 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In most cases, however, the myeloma cells collect in many bones, often forming many tumors and causing other problems.
Because people with MM have an abnormally large number of identical plasma cells, they also have too much of one type of antibody.
The tumor, its products, and the host response to it result in a number of organ dysfunctions and symptoms of bone pain or fracture, renal failure, susceptibility to infection, anemia, hypercalcemia, and occasionally clotting abnormalities, neurologic symptoms, and vascular manifestations of hyperviscosity.
Unfortunately, MM is presently considered an incurable disease and the overall survival of MM patients has remained essentially unchanged at a median of 3-4 years, despite intense efforts over the last ˜3 decades to improve on the activity of cytotoxic chemotherapy-based therapies for this disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aplidine for multiple myeloma treatment
  • Aplidine for multiple myeloma treatment
  • Aplidine for multiple myeloma treatment

Examples

Experimental program
Comparison scheme
Effect test

example 1

MTT Calorimetric Survival Assay

[0042] Cell survival was examined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical, St Louis, Mo.) colorimetric assay, as previously described (Mitsiades C. S. et al. Blood. 2001, 98, 795-804; Mitsiades N. et al. Proc Natl Acad Sci USA. 2002, 99, 14374-14379; Mitsiades N. et al. Blood. 2003, 101, 2377-2380). Briefly, cells were plated in 48-well plates at 70% to 80% confluence in the presence of 2.5% fetal bovine serum (FBS) and in the presence of Aplidine at final concentration of 0-100 nM or DMSO vehicle control. At the end of each treatment, cells were incubated with 1 mg / mL MTT for 4 hours at 37° C.; a mixture of isopropanol and 1 N HCl (23:2, vol / vol) was then added under vigorous pipetting to dissolve the formazan crystals. Dye absorbance (A) in viable cells was measured at 570 nm, with 630 nm as a reference wavelength. Cell viability was estimated as a percentage of the value of untreated controls. Al...

example 2

Stable Transfections of Bcl-2 and Constitutively Active Akt

[0049] MM-1S cells were stably transfected with plasmid vector encoding myristoylated (constitutively active) Akt or Bcl-2 (Upstate Biotechnologies, Lake Placid, N.Y.) or with empty (neo) vectors, and were performed using Lipofectamine 2000 (Life Technologies), followed by cultures in G418-containing selection media, as previously described (Mitsiades C. S. et al. Oncogene. 2002, 21, 5673-5683; Mitsiades N. et al. Proc Natl Acad Sci USA. 2002, 99, 14374-14379).

Results: Aplidine Overcomes the Anti-Apoptotic Effect of Bcl-2 or Constitutively Active Akt

[0050] Because of the roles of Bcl-2 and the PI-3K / Akt cascade in the regulation of drug-induced apoptosis in MM and other neoplasias, we also characterized the activity of aplidine in MM-1S human MM cells stably transfected with Bcl-2 or myristoylated Akt constructs vs. empty vector-transfected control MM-1S cells. We observed that Bcl-2- or myrAkt-transfected cells did not...

example 3

[0051] Co-Culture Assays of MM Cells with Bone Marrow Stromal Cells (BMSCs)

[0052] When adhering to BMSCs, MM cells have reduced sensitivity to conventional anti-MM therapies, such as dexamethasone or cytotoxic chemotherapeutics (Chauhan D. et al. Blood. 1996, 87, 1104-1112). This form of drug resistance is considered a key reason why MM patients eventually relapse when they receive treatment based on administration of glucocorticoids and / or cytotoxic chemotherapy. In contrast, among recently developed therapies for MM, anti-tumor activity against in cases of chemo-resistant or steroid-resistant MM has been achieved by classes of drugs, e.g. proteasome inhibitors (Hideshima T. et al. Cancer Res. 2001, 61, 3071-3076), which can overcome the protective effects of BMSCs on MM cells. We therefore investigated whether aplidine can also overcome the molecular sequelae of the interaction of BMSCs with MM cells and achieve anti-MM activity in this context. We thus performed in vitro co-cult...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pharmaceutical compositionaaaaaaaaaa
massaaaaaaaaaa
resistanceaaaaaaaaaa
Login to View More

Abstract

Aplidine and aplidine analogues are used in the manufacture of a medicament for treating multiple myeloma.

Description

FIELD OF THE INVENTION [0001] The present invention relates to the use of aplidine and analogues in the treatment of cancer, in particular in the treatment of multiple myeloma. BACKGROUND OF THE INVENTION [0002] Multiple myeloma represents a malignant proliferation of plasma cells derived from a single clone. The terms multiple myeloma and myeloma may be used interchangeably. [0003] Plasma cells produce antibodies, proteins that move through the bloodstream to help the body get rid of harmful substances. Each type of plasma cell responds to only one specific substance by making a large amount of one kind of antibody. These antibodies find and act against that one substance. Because the body has many types of plasma cells, it can respond to many substances. When cancer involves plasma cells, the body keeps producing more and more of these cells. The unneeded plasma cells—all abnormal and all exactly alike—are called myeloma cells. Myeloma cells tend to collect in the bone marrow and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/12C07K7/60A61K38/15A61P35/00
CPCA61K38/15A61P19/00A61P35/00
Inventor BERTINO, JOSEPH R.MEDINA, DANIELFAIRCLOTH, GLYNN THOMASMITSIADES, CONSTANTINE S.ANDERSON, KENNETHMITSIADES, NICHOLAS
Owner PHARMA MAR U